Table IV.

Matrix effect and recovery of FTFSLDTSK, VLIYFTSSLHSGVPSR, STAYLQMNSLR and P14R.

Nominal concentration of bevacizumab, µg/ml	Selected peptides FTFSLDTSK		VLIYFTSSLHSGVPSR		STAYLQMNSLR		IS P14R
	Mean ± SD	RSD,%	Mean ± SD	RSD,%	Mean ± SD	RSD, %	Mean ± SD	RSD,%
Matrix effect, % (n=10)
10	32.98±3.27	4.82	46.06±6.53	6.15	37.21±3.86	5.04	82.30±3.28	10.14
50	31.83±1.67	6.28	43.84±3.44	5.27	38.46±2.57	4.95
200	34.80±1.31	4.1	42.12±0.99	3.24	36.93±1.26	3.47
IS-normalized matrix factor, % (n=10)
10	41.87±3.47	5.49	59.52±7.16	6.55	48.03±4.96	4.93
50	41.89±2.54	8.65	57.60±3.21	7.66	49.65±4.28	7.25
200	44.24±4.18	6.41	53.48±3.90	6.24	47.67±3.95	5.6
Recovery, % (n=10)
10	22.86±1.10	15.61	23.15±1.42	14.17	22.74±1.28	12.79	77.47±4.49	6.05
50	22.11±1.39	5.24	21.78±1.15	7.84	23.29±1.47	8.79
200	23.59±0.97	3.78	24.65±0.80	2.34	22.91±0.94	2.97

IS, internal standard; P₁₄R, Pro14-Arg.